Oops! This Content is Members Only

Recent Content

• Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma
• Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
• Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma
• Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
• Circulating miR-448 acts as a potential diagnostic biomarker for multiple myeloma
• Daratumumab-Based Triplet Therapy Shows Benefits for Relapsed/Refractory Multiple Myeloma
• Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia
• Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
• Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model
• A Rare Case of Extra-Medullary Portacaval Plasmacytoma in a Patient With Relapsed Multiple Myeloma